In-silico Molecular Docking and ADMET predictions of Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-Dione Analogues as promising Antimicrobial, Antioxidant and Anticancer agents

Reference

• S. Pallerla, A. R. M. Abdul, J. Comeau, and S. Jois, “Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer,” International Journal of Molecular Sciences 22, no. 2 (2021): 779–16. doi:10.3390/ijms22020779
   PubMed Web of Science ®Google Scholar
• F. J. Alipoor, M. H. Asadi, and M. Torkzadeh-Mahani, “Miat lncRNA is Overexpressed in Breast Cancer and Its Inhibition Triggers Senescence and G1 Arrest in MCF7 Cell Line,” Journal of Cellular Biochemistry 119, no. 8 (2018): 6470–81. doi:10.1002/jcb.26678
   PubMed Web of Science ®Google Scholar
• A. Moshfegh, A. Jalali, A. Salehzadeh, and A. Sadeghi Jozani, “Biological Synthesis of Silver Nanoparticles by Cell-Free Extract of Polysiphonia Algae and Their Anticancer Activity against Breast Cancer MCF-7 Cell Lines,” Micro & Nano Letters 14, no. 5 (2019): 581–4. doi:10.1049/mnl.2018.5260
   Web of Science ®Google Scholar
• D. Daddiouaissa, A. Amid, N. A. Kabbashi, F. A. A. Fuad, A. A. M. Elnour, and M. A. K. M. S. Epandy, “Antiproliferative Activity of Ionic Liquid-Graviola Fruit Extract against Human Breast Cancer (MCF-7) Cell Lines Using Flow Cytometry Techniques,” Journal of Ethnopharmacology 236 (2019): 466–73. doi:10.1016/j.jep.2019.03.003
   PubMed Web of Science ®Google Scholar
• S. E. S. Abbas, R. F. George, E. M. Samir, M. M. A. Aref, and H. A. Abdel-Aziz, “Synthesis and Anticancer Activity of Some Pyrido[2,3-d]Pyrimidine Derivatives as Apoptosis Inducers and Cyclin-Dependent Kinase Inhibitors,” Future Medicinal Chemistry 11, no. 18 (2019): 2395–414. doi:10.4155/fmc-2019-0050
   PubMed Web of Science ®Google Scholar
• Gülhan Turan-Zitouni, Mehlika Dilek Altıntop, Zafer Asım Kaplancıklı, Ahmet Özdemir, Fatih Demirci, Sinem Ilgın, Özlem Atlı, and Gamze Göger, “Synthesis and Evaluation of Thiazole – Pyrimidine Derivatives as New Anticandidal and Cytotoxic Agents,” Pharmaceutical Chemistry Journal 48, no. 7 (2014): 452–5. doi:10.1007/s11094-014-1130-7
   Web of Science ®Google Scholar
• M. D. Altıntop, Z. A. Kaplancıklı, G. A. Ciftci, and R. Demirel, “Synthesis and Biological Evaluation of Thiazoline Derivatives as New Antimicrobial and Anticancer Agents,” European Journal of Medicinal Chemistry 74 (2014): 264–77. doi:10.1016/j.ejmech.2013.12.060
   PubMed Web of Science ®Google Scholar
• C. Mallikarjunaswamy, L. Mallesha, D. G. Bhadregowda, and Othbert. Pinto, “Studies on Synthesis of Pyrimidine Derivatives and Their Antimicrobial Activity,” Arabian Journal of Chemistry 10 (2017): S484–S490. doi:10.1016/j.arabjc.2012.10.008
   Web of Science ®Google Scholar
• A. Al-Mulla, “A Review: Biological Importance of Heterocyclic Compounds,” Der Pharma Chemica 9, no. 13 (2017): 141–7.
   Google Scholar
• Y. Huang, J. Liao, W. Wang, H. Liu, and H. Guo, “Synthesis of Heterocyclic Compounds through Nucleophilic Phosphine Catalysis,” Chemical Communications 56, no. 97 (2020): 15235–81. doi:10.1039/D0CC05699E
   PubMed Web of Science ®Google Scholar
• A. B. A. El-Gazzar, A. M. Gaafar, and A. S. Aly, “Synthesis of Some New Thiazolo[3,2-a]Pyrido[2,3-d]Pyrimidinones and Isoxazolo[5’,4’:4,5]Thiazolo[3,2-a]Pyrido[2,3-d]Pyrimidinone,” Bioorganic and Medicinal Chemistry Letters 19, no. 13 (2009): 3392–7. doi:10.1016/j.bmcl.2009.05.044
   PubMed Web of Science ®Google Scholar
• M. J. Shanmugam, and T. M. Das, “A Concise Pathway to Synthesize a Novel Class of Pyrido(2,3-d)pyrimidine-C-b-D-Glycosides,” Carbohydrate Research 368 (2013): 40–6. doi:10.1016/j.carres.2012.11.013
   PubMed Web of Science ®Google Scholar
• A. Ashraf, M. Khalid, M. N. Tahir, M. Yaqub, M. M. Naseer, G. M. Kamal, B. Saifullah, A. A. C. Braga, Z. Shafiq, and W. Rauf, “A Facile and Concise Route to (Hydroxybenzoyl) Pyrido[2,3-d]Pyrimidine Heterocycle Derivatives: synthesis, and Structural, Spectral and Computational Exploration,” RSC Advances 9, no. 59 (2019): 34567–80. doi:10.1039/C9RA05415D
   PubMed Web of Science ®Google Scholar
• Nuran Kahriman, Kıvanç Peker, Vildan Serdaroğlu, Ali Aydın, Asu Usta, Seda Fandaklı, and Nurettin Yaylı, “Novel 2-Amino-4-Aryl-6-Pyridopyrimidines and N-Alkyl Derivatives: Synthesis, Characterization and Investigation of Anticancer, Antibacterial Activities and DNA/BSA Binding Affinities,” Bioorganic Chemistry 99 (2020): 103805. doi:10.1016/j.bioorg.2020.103805
   PubMed Web of Science ®Google Scholar
• R. Dummer, P. A. Ascierto, H. J. Gogas, A. Arance, M. Mandala, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsova, R. Gutzmer, et al, “Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): a Multicentre, Open-Label, Randomised Phase 3 Trial,” The Lancet Oncology 19, no. 5 (2018): 603–15. doi:10.1016/S1470-2045(18)30142-6
   PubMed Web of Science ®Google Scholar
• J. Larkin, P. A. Ascierto, B. Dréno, V. Atkinson, G. Liszkay, M. D. M. Maio, M. Mandalà, L. Demidov, D. Stroyakovskiy, L. Thomas, et al, “Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma,” New England Journal of Medicine 371, no. 20 (2014): 1867–76. doi:10.1056/NEJMoa1408868
   PubMed Web of Science ®Google Scholar
• G. V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. J. Grob, et al, “Dabrafenib and Trametinib versus Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma: A Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial,” The Lancet Oncology 386, no. 9992 (2015): 444–51. doi:10.1016/S0140-6736(15)60898-4
   Google Scholar
• A. O. Abdelhamid, S. M. Gomha, N. A. Abdelriheem, and S. M. Kandeel, “Synthesis of New 3-Heteroarylindoles as Potential Anticancer Agents,” Molecules 21, no. 7 (2016): 929. doi:10.3390/molecules21070929
   PubMed Web of Science ®Google Scholar
• E. M. Grivsky, S. Lee, C. W. Sigel, D. S. Duch, and C. A. Nichol, “Synthesis and Antitumor Activity of 2,4-Diamino-6-(2,5-Dimethoxybenzyl)-5-Met Hylpyrido[2,3-d] Pyrimidine,” Journal of Medicinal Chemistry 23, no. 3 (1980): 327–9. doi:10.1021/jm00177a025
   PubMed Web of Science ®Google Scholar
• M. Font, Á. González, J. A. Palop, and C. Sanmartín, “New Insights into the Structural Requirements for Pro-Apoptotic Agents Based on 2,4-Diaminoquinazoline, 2,4-Diaminopyrido[2,3-d]Pyrimidine and 2,4-Diaminopyrimidine Derivatives,” European Journal of Medicinal Chemistry 46, no. 9 (2011): 3887–99. doi:10.1016/j.ejmech.2011.05.060
   PubMed Web of Science ®Google Scholar
• I. 0. Donkor, C. L. Klein, L. Liang, N. Zhu, E. Bradley And, and A. M. Clark, “Synthesis and Antimicrobial Activity of 6,7-Annulated Pyrid0[2,3-d]Pyrimidines,” Journal of Pharmaceutical Sciences 84, no. 5 (1995): 661–4. doi:10.1002/jps.2600840526
   PubMed Web of Science ®Google Scholar
• S. Ohno, N. Matsumoto, M. Watanabe, and S. Nakajin, “Flavonoid Inhibition of Overexpressed Human 3β-Hydroxysteroid Dehydrogenase Type II,” Journal of Steroid Biochemistry & Molecular Biology 88, no. 2 (2004): 175–82. doi:10.1016/j.jsbmb.2003.11.007
   PubMed Web of Science ®Google Scholar
• R. V. Chikhale, R. P. Bhole, P. B. Khedekar, and K. P. Bhusari, “Synthesis and Pharmacological Investigation of 3-(substituted1-Phenylethanone)-4-(Substitutedphenyl)-1,2,3,4-Tetrahydropyrimidine-5-Carboxylates,” European Journal of Medicinal Chemistry 44, no. 9 (2009): 3645–53. doi:10.1016/j.ejmech.2009.02.021
   PubMed Web of Science ®Google Scholar
• Sham M. Sondhi, Nirupma Singh, Monika Johar, and Ashok Kumar, “Synthesis, anti-Inflammatory and Analgesic Activities Evaluation of Some Mono, bi and Tricyclic Pyrimidine Derivatives,” Bioorganic & Medicinal Chemistry 13, no. 22 (2005): 6158–66. doi:10.1016/j.bmc.2005.06.063
   PubMed Web of Science ®Google Scholar
• Anu Agarwal, Neena Goyal, Prem M. S. Chauhan, and Suman Gupta, Ramesh Ashutosh, “Dihydropyrido[2,3-d]Pyrimidines as a New Class of Antileishmanial Agents,” Bioorganic & Medicinal Chemistry 13, no. 24 (2005): 6678–84. doi:10.1016/j.bmc.2005.07.043
   PubMed Web of Science ®Google Scholar
• A. Pastor, R. Alajarin, J. J. Vaquero, J. Alvarez-Builla, M. Casa-Juana, C. Sunkel, J. G. Priego, I. Fonseca, and J. Sanz-Aparicio, “Synthesis and Structure of New Pyrido[2,3-Dlpyrimidine Derivatives with Calcium Channel Antagonist Activity,” Tetrahedron 50, no. 27 (1994): 8085–98. doi:10.1016/S0040-4020(01)85291-1
   Web of Science ®Google Scholar
• S. Prachayasittikul, R. Pingaew, A. Worachartcheewan, N. Sinthupoom, V. Prachayasittikul, S. Ruchirawat, and V. Prachayasittikul, “Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents,” Mini-Reviews in Medicinal Chemistry 17, no. 10 (2017): 869–901. doi:10.2174/1389557516666160923125801
   PubMed Web of Science ®Google Scholar
• A. Ayati, S. Moghimi, M. Toolabi, and A. Foroumadi, “Pyrimidine-Based EGFR TK Inhibitors in Targeted Cancer Therapy,” European Journal of Medicinal Chemistry 221 (2021): 113523. doi:10.1016/j.ejmech.2021.113523
   PubMed Web of Science ®Google Scholar
• J. Zhuang, and S. Ma, “Recent Development of Pyrimidine Containing Antimicrobial Agents,” Chemmedchem. 15, (2020): 1875–1886.
   PubMed Web of Science ®Google Scholar
• N. T. El-Shamy, A. M. Alkaoud, R. K. Hussein, M. A. Ibrahim, A. G. Alhamzani, and M. M. Abou-Krisha, “DFT, ADMET and Molecular Docking Investigations for the Antimicrobial Activity of 6,6’-Diamino-1,1′,3,3’-Tetramethyl-5,5’-(4- Chlorobenzylidene)Bis[Pyrimidine-2,4(1H,3H)-Dione],” Molecules 27, no. 3 (2022): 620–1-17. doi:10.3390/molecules27030620
   PubMed Web of Science ®Google Scholar
• K. M. Rana, J. Maowa, A. Alam, S. Dey, A. Hosen, I. Hasan, Y. Fujii, Y. Ozeki, and S. M. A. Kawsar, “In Silico DFT Study, Molecular Docking, and ADMET Predictions of Cytidine Analogs with Antimicrobial and Anticancer Properties,” In,” In Silico Pharmacology 9, no. 1 (2021): 1–24. doi:10.1007/s40203-021-00102-0
   PubMedGoogle Scholar
• G. Palermoa, and M. Vivoa, “Computational Chemistry for Drug Discovery,” Encyclopedia of Nanotechnology (2015).
   Google Scholar
• H. Hadni, and M. Elhallaoui, “3D-QSAR, Docking and ADMET Properties of Aurone Analogues as Antimalarial Agents,” Heliyon 6, no. 4 (2020): e03580–11. doi:10.1016/j.heliyon.2020.e03580
   PubMed Web of Science ®Google Scholar
• S. B. Olasupo, A. Uzairu, G. Shallangwa, and S. Uba, “QSAR Modeling, Molecular Docking and ADMET/Pharmacokinetic Studies: A Chemometrics Approach to Search for Novel Inhibitors of Norepinephrine Transporter as Potent Antipsychotic Drugs,” Journal of the Iranian Chemical Society 17, no. 8 (2020): 1953–66. doi:10.1007/s13738-020-01902-5
   Web of Science ®Google Scholar
• G. Moroy, V. Y. Martiny, P. Vayer, B. O. Villoutreix, and M. A. Miteva, “Toward in Silico Structure-Based ADMET Prediction in Drug Discovery,” Drug Discovery Today. 17, no. 1-2 (2012): 44–55. doi:10.1016/j.drudis.2011.10.023
   PubMed Web of Science ®Google Scholar
• M. A. Ejalonibu, A. A. Elrashedy, M. M. Lawal, M. E. Soliman, S. C. Sosibo, H. M. Kumalo, and N. N. Mhlongo, “Dual Targeting Approach for Mycobacterium tuberculosis Drug Discovery: insights from DFT Calculations and Molecular Dynamics Simulations,” Structural Chemistry 31, no. 2 (2019): 1–15.
   Web of Science ®Google Scholar
• E. Shirbhate Divya, P. Patel, V. K. Patel, R. Veerasamy, and H. Rajak, “Exploration of Anticancer Potential of Hydroxamate Derivatives as Selective HDAC8 Inhibitors Using Integrated Structure and Ligand Based Molecular Modeling Approach,” Indian Journal of Chemistry 60B 1 (2021): 136–47.
   Google Scholar
• Sibel Eken Korkut, Erem Ahmetali, Mesut Bilgi, Özgül Karataş, Yusuf Yerli, Ayşegül Peksel, and M. Kasım Şener, “Synthesis and Antioxidant Activity of Zinc(II) Phthalocyanine Tetranitroxide,” Polyhedron 197 (2021): 115045–17. doi:10.1016/j.poly.2021.115045
   Web of Science ®Google Scholar
• V. A. Verma, B. Halu, A. R. Saundane, and R. S. Meti, “Synthesis, Biological Validation, and Docking Studies of Novel Purine Derivatives Containing Pyridopyrimidine, Pyrazolopyridine, and Pyranonapthyridine Rings,” Polycyclic Aromatic Compounds 42, no. 6 (2022): 3694–716. doi:10.1080/10406638.2020.1871384
   Web of Science ®Google Scholar
• S. Balachandar, M. Dhandapani, I. V. M. V. Enoch, and S. Suganthi, “Structural Analysis, Molecular Docking and DFT Calculations of Bis(Pyrazolium Picrate) Monohydrate Interaction with Calf Thymus DNA and Microbes,” ChemistrySelect 2, no. 29 (2017): 9298–311. doi:10.1002/slct.201701484
   Web of Science ®Google Scholar
• F. Denizot, and R. Lang, “Rapid Colorimetric Assay for Cell Growth and Survival: Modifications to the Tetrazolium Dye Procedure Giving Improved Sensitivity and Reliability,” Journal of Immunological Methods 89, no. 2 (1986): 271–7. doi:10.1016/0022-1759(86)90368-6
   PubMed Web of Science ®Google Scholar
• M. Erola, I. Celika, E. Uzunhisarciklic, and G. Kuyucuklu, “Synthesis, Molecular Docking, and DFT Studies of Some New 2,5-Disubstituted Benzoxazoles as Potential Antimicrobial and Cytotoxic Agents,” Polycyclic Aromatic Compound 42, no. 4 (2020): 1–19.
   Web of Science ®Google Scholar
• N. P. Kumar, S. Thatikonda, R. Tokala, S. S. Kumari, U. J. Lakshmi, C. Godugu, N. Shankaraiah, and A. Kamal, “Sulfamic Acid Promoted One-Pot Synthesis of Phenanthrene Fused-Dihydrodibenzo-Quinolinones: Anticancer Activity, Tubulin Polymerization Inhibition and Apoptosis Inducing Studies,” Bioorganic & Medicinal Chemistry 26, no. 8 (2018): 1996–2008. doi:10.1016/j.bmc.2018.02.050
   PubMed Web of Science ®Google Scholar
• N. K. Duddukuri, S. Thatikonda, C. Godugu, R. A. Kumar, and N. Doijad, “Synthesis of Novel Thiophene-Chalcone Derivatives as Anticancer- and Apoptosis-Inducing Agents,” ChemistrySelect 3, no. 24 (2018): 6859–64. doi:10.1002/slct.201800613
   Web of Science ®Google Scholar
• R. Verma, I. Bairy, M. Tiwari, G. V. Bhat, and G. G. Shenoy, “In Silico Studies, Synthesis and Anticancer Activity of Novel Diphenyl Ether-Based Pyridine Derivatives,” Molecular Diversity 23, no. 3 (2018): 1–14.
   PubMed Web of Science ®Google Scholar
• K. S. Bhullar, N. O. Lagarón, E. M. McGowan, I. Parmar, A. Jha, B. P. Hubbard, and H. P. V. Rupasinghe, “Kinase-Targeted Cancer Therapies: progress, Challenges and Future Directions,” Molecular Cancer 17, no. 1 (2018): 1–20. doi:10.1186/s12943-018-0804-2
   PubMedGoogle Scholar
• I. M. Khana, M. Islama, S. Shakyaa, N. Alamb, S. Imtiaza, and M. R. Islam, “Synthesis, Spectroscopic Characterization, Antimicrobial Activity, Molecular Docking and DFT Studies of Proton Transfer (H-Bonded) Complex of 8-Aminoquinoline (Donor) with Chloranilic Acid (Acceptor),” Journal of Biomolecular Structure and Dynamics 40 (2021): 12194–208.
   PubMed Web of Science ®Google Scholar
• M. Shweta, and D. Rashmi, “In-Vitro ADME Studies of TUG-891, a GPR-120 Inhibitor Using Swiss ADME Predictor,” Journal of Drug Delivery & Therapeutics 9, no. 3 (2019): 266–369.
   Google Scholar
• M. Erol, I. Celik, E. Uzunhisarcikli, and G. Kuyucuklu, “Synthesis, Molecular Docking and DFT Studies of Some New 2,5-Disubstituted Benzoxazoles as Potential Antimicrobial and Cytotoxic Agents,” Polycyclic Aromatic Compounds 42 (2020): 1679–96.
   Web of Science ®Google Scholar
• A. Daina, O. Michielin, and V. Zoete, “SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Druglikeness and Medicinal Chemistry Friendliness of Small Molecules,” Scientific Reports 7, no. 1 (2017): 1–13. doi:10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• R. Bhutani, D. P. Pathak, G. Kapoor, A. Husain, R. Kant, and M. A. Iqbal, “Synthesis, Molecular Modelling Studies and ADME Prediction of Benzothiazole Clubbed oxadiazole-Mannich Bases, and Evaluation of Their anti-Diabetic Activity through in Vivo Model,” Bioorganic Chemistry 77 (2018): 6–15. doi:10.1016/j.bioorg.2017.12.037
   PubMed Web of Science ®Google Scholar
• A. Ali, M. E. I. Badawy, R. Shah, W. Rehman, and Y. El, “Synthesis, Characterization and in-Silico ADMET Screening of Mono- and Di- Hydrazides and Hydrazones,” Pelagia Res. Libr. Der 8 (2017): 446–60.
   Google Scholar
• C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development q Settings,” Advanced Drug Delivery Reviews 64 (2012): 4–17. doi:10.1016/j.addr.2012.09.019
   Web of Science ®Google Scholar
• A. K. Ghose, V. N. Viswanadhan, and J. J. Wendoloski, “A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases,” Journal of Combinatorial Chemistry 1, no. 1 (1999): 55–68. doi:10.1021/cc9800071
   PubMedGoogle Scholar
• W. J. Egan, K. M. Merz, and J. J. Baldwin, “Prediction of Drug Absorption Using Multivariate Statistics,” Journal of Medicinal Chemistry 43, no. 21 (2000): 3867–77. doi:10.1021/jm000292e
   PubMed Web of Science ®Google Scholar
• I. Muegge, S. L. Heald, and D. Brittelli, “Simple Selection Criteria for Drug-like Chemical Matter,” Journal of Medicinal Chemistry 44, no. 12 (2001): 1841–6. doi:10.1021/jm015507e
   PubMed Web of Science ®Google Scholar
• D. F. Veber, S. R. Johnson, H. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, “Molecular Properties That Influence the Oral Bioavailability of Drug Candidates,” Journal of Medicinal Chemistry 45, no. 12 (2002): 2615–23. doi:10.1021/jm020017n
   PubMed Web of Science ®Google Scholar
• C. P. Chen, C. C. Chen, C. W. Huang, and Y. C. Chang, “Evaluating Molecular Properties Involved in Transport of Small Molecules in Stratum Corneum: A Qualitative Structure- Activty Relationship for Skin Permeation,” Molecules 23, no. 4 (2018): 1–17.
   Web of Science ®Google Scholar
• G. Zhang, S. Guo, H. Cui, and J. Qi, “Virtual Screening of Small Molecular Inhibitors against DprE1,” Molecules 23, no. 3 (2018): 1–9.
   Web of Science ®Google Scholar